advertisement
Abstract #74295 Published in IGR 19-1
Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients
Brennan N; Dehabadi MH; Nair S; Quartilho A; Bunce C; Reekie I; Obikpo RInternational Journal of Ophthalmology 2017; 10: 1251-1254
AIM: To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (IOP)on current therapy. METHODS: Pre- and post-switch IOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in IOP post-pre switch was analyzed using a 2-sided Student's paired t-test at the 5% significance level. RESULTS: There was a statistically significant mean reduction in IOP at the first follow up visit, which was maintained at subsequent follow up visits for patients regardless of diagnosis, or pre-switch treatment (P<0.001). Subgroup analysis also demonstrated a statistically significant mean reduction in IOP when looking at OHT patients only, as well as patients with any diagnosis switched from latanoprost monotherapy to bimatoprost monotherapy (P<0.001). CONCLUSION: This is the largest independent data set which supports switching glaucoma patients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy.
Moorfields Eye Hospital NHS Foundation Trust, London EC1V 2PD, UK.
Full articleClassification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
